CLIA CCC common mistakes
CLIA CCC · Understand the traps and how to avoid them.
Reporting a donor unit as eligible for transfusion when only the ABO/Rh type and antibody screen have been completed, without confirming that the required infectious-disease testing (HIV, HCV, HBV, syphilis, and any required NAT) is finalized and negative.
Candidates memorize the 'type and screen' workflow from the patient-testing side and transfer it to donor release, forgetting that donor eligibility is a separate regulatory gate. The two pathways look similar on paper, so the distinction blurs under time pressure.
What to do instead
Before answering any donor-release item, explicitly list the release criteria in order: negative infectious-disease testing, negative NAT where required, acceptable donor history, and completed component labeling. Treat 'type and screen complete' as necessary but never sufficient for release.
Choosing the ABO-compatible but not identical component for a recipient when an identical component is available, or reversing the major/minor crossmatch rule for plasma versus red cells.
Candidates learn the red-cell rule (recipient antibody against donor red cells) and then apply it mechanically to plasma, where the concern is donor antibody against recipient red cells. The directionality of compatibility flips between products and is easy to invert.
What to do instead
Anchor every compatibility question to the product: for red cells ask 'can the recipient's antibodies lyse the donor cells?'; for plasma ask 'can the donor's antibodies lyse the recipient's cells?'. Write the direction down before selecting an answer, and prefer ABO-identical over merely compatible when both are offered.
Interpreting a positive antibody screen as an antibody identity without performing or interpreting the panel and autocontrol, and failing to recognize that a positive autocontrol points away from an alloantibody.
The screen is taught as a yes/no gate, and candidates stop reasoning once it is positive. The autocontrol is a small field on the worksheet and is easy to skip, so the logic that separates alloantibody from autoantibody or from a warm autoantibody never gets applied.
What to do instead
Adopt a fixed sequence for every positive screen: check autocontrol first, then panel pattern, then rule-out cells, then enhancement or enzyme-treated cells as indicated. State in your reasoning which step distinguishes alloantibody from autoantibody before choosing an answer.
Calling a blood culture positive and identifying an organism from a single bottle's Gram stain without accounting for the number of bottles positive, time to positivity, or whether the organism is a recognized skin commensal.
Candidates treat any growth as significant because the question presents a Gram stain result as the finding. Contamination assessment requires integrating bottle count and time to positivity, which are often stated in the stem but not flagged as decision-relevant.
What to do instead
For every positive blood culture item, tally how many bottles and sets are positive and the time to detection before interpreting. Apply the commensal rule: a single bottle positive for coagulase-negative staphylococci, diphtheroids, or similar in a short window suggests contamination and warrants repeat culture rather than immediate treatment conclusions.
Selecting an antimicrobial susceptibility interpretation by matching the drug to the organism's usual susceptibility pattern instead of applying the current breakpoint category reported for that organism-drug pair, including intrinsic resistance.
Candidates rely on memorized 'typical' susceptibility (for example, that a given species is usually susceptible to a drug) rather than reading the reported category. Intrinsic resistance is especially easy to miss because the drug may look clinically reasonable.
What to do instead
When a susceptibility item appears, first ask whether the organism is intrinsically resistant to that drug (for example, Klebsiella against ampicillin, or Enterococcus against cephalosporins). If not, use only the reported S/I/R category from the stem and never infer susceptibility from species reputation.
Correcting a urinalysis or body-fluid result for a preservative or dilution factor when the specimen was collected without preservative, or applying a correction that the collection method does not require.
Candidates memorize correction formulas as a checklist and apply them whenever they see a number that looks off, without first confirming the collection tube type stated in the stem. The correction becomes a reflex rather than a conditional step.
What to do instead
Before any arithmetic, identify the collection container and preservative from the stem. Apply dilution or preservative corrections only when that specific container is named; if the stem does not specify, state the assumption explicitly and answer for the most common collection type rather than silently correcting.
Treating a single elevated tumor marker or a single low specificity serology result as diagnostic, without confirming by a second method or considering the pretest probability and known false-positive causes.
Exam items present one abnormal value and candidates read it as the answer. Tumor markers and serologies are frequently ordered as confirmation but are taught in isolation, so the confirmatory step and the false-positive differential get dropped.
What to do instead
For any single-marker item, ask three questions before answering: what is the pretest probability, what confirmatory or orthogonal method is standard, and what common conditions cause a false positive (rheumatoid factor, heterophile antibody, pregnancy, recent transfusion). Choose the answer that reflects confirmation, not the first abnormal number.
Reporting a molecular result as positive based on amplification signal alone without reviewing the internal control, the negative control, and whether the assay's limit of detection or inhibition flags were met.
Candidates focus on the target signal because that is the headline of the question. Internal controls are listed as extra data and are easy to treat as background rather than as the gate that determines whether the target result is valid.
What to do instead
For every molecular result item, evaluate controls in order: negative control must be negative, internal control must amplify, and no inhibition flag may be present. If any control fails, the run is invalid and the answer is 'repeat', regardless of how strong the target signal is.
Applying a Westgard rule incorrectly by flagging a run for a single control exceeding 2 SD, or by missing that a 4-1s or 10x violation requires consecutive runs rather than a single measurement.
Candidates conflate warning rules with rejection rules and lose track of whether a rule spans one run or several. The 1-2s rule is a warning, not a rejection, and the multi-run rules require counting across runs, which is easy to miscount.
What to do instead
Before judging a QC item, write the rule definitions: 1-2s is a warning only; 2-2s, R-4s, 4-1s, and 10x are rejection rules, with 4-1s and 10x evaluated across consecutive runs. Count the actual data points in the stem against each definition rather than pattern-matching the rule name.
Classifying a laboratory test as waived, moderate, or high complexity by the instrument's brand or by the department it sits in, rather than by the test's published complexity category and the manufacturer's cleared instructions.
Candidates map complexity to familiar equipment (a benchtop analyzer 'must be moderate') instead of to the CLIA test categorization. The categories are assigned per test, not per instrument or per room, and the distinction drives personnel and QC requirements.
What to do instead
For any complexity question, identify the specific test and its CLIA category from the stem or from the manufacturer's cleared labeling, then apply the corresponding personnel, QC, and proficiency-testing requirements. Never infer complexity from the analyzer model or the laboratory section.